Global digital therapeutics innovation leader, DarioHealth Corp. announced the launch of the Dario-powered digital diabetes program on Walmart.com.
DarioHealth Expands Retail Distribution Through Walmart.com
BENTONVILLE, Arkansas and NEW YORK, Dec. 3, 2019 /PRNewswire/ -- Global digital therapeutics innovation leader, DarioHealth Corp. (NASDAQ: DRIO) announced today the launch of the Dario-powered digital diabetes program on Walmart.com.
Walmart is the largest retailer in the world and is the second largest e-commerce retailer in the U.S. It is also an innovator in healthcare, piloting several initiatives such as opening its own Walmart Health centers and creating a Home Health Care section on Walmart.com.
The Dario digital diabetes app is among the most downloaded and highest rated healthcare apps, with a 4.9/5.0 star rating and over 8,000+ reviews on the Apple store. Its Net Promoter Score (NPS), a measure of willingness of customers to recommend a company’s products or services to others, is +77, considered “world class” and the highest in its category, on a -100 - +100 scale.
“Walmart strives to offer its shoppers health solutions that will help them manage their own health in the most efficient way possible. We are excited to access Walmart’s online distribution channel given the extremely high volume of annual visitors. We will offer Walmart’s consumers MyDario™, our complete digital solution to manage diabetes, hypertension, nutrition and exercise. Our system is affordable and supported by a large body of clinical evidence that we believe demonstrates that Dario significantly and quickly improves the health and wellness of its users. We believe that the positive results seen while using our system reinforces engagement and are part of the reason why users rate Dario as one of the best solutions for managing chronic conditions,” said Olivier Jarry, DarioHealth’s President and Chief Commercial Officer.
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital health company serving its users with dynamic mobile health solutions. In today’s day and age, knowledge of health and treatment is being democratized, and we believe people deserve to know everything about their own health and have the best tools to manage their condition. DarioHealth employs a revolutionary approach whereby harnessing big data, we have developed a novel method for chronic disease data management, empowering people to analyze and personalize self-diabetes management in a totally new way without having the disease slow them down. DarioHealth has a commercial office in New York with an R&D center in Caesarea, Israel.
For more information, visit http://mydario.investorroom.com/.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the “Company”) related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” or “continue” are intended to identify forward-looking statements. For example, when the Company discusses its belief that the existing body of evidence with respect to its system demonstrates that Dario significantly and quickly improves the health and wellness of its users and the belief that the positive results seen while using its system reinforces engagement and are part of the reason why users rate Dario as one of the best solutions for managing chronic conditions, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate Contact:
Claudia Levi
Content & Communications Manager
claudia@mydario.com
Tel: +1-347-767-4220
View original content to download multimedia:http://www.prnewswire.com/news-releases/walmart-starts-distributing-the-dariohealth-digital-diabetes-management-system-300968169.html
SOURCE DarioHealth Corp.
Company Codes: NASDAQ-SMALL:DRIO, Berlin:LS1N, Munich:LS1P, Stuttgart:LS1N
